Furthermore, inhibition of PAR2 augmented the effect of gefitinib in cell proliferation, migration and apoptosis in gefitinib-sensitive and -resistant NSCLC cells while targeting PAR2 promoted gefitinib to modulate ERK signaling and EMT. Here, F2RL1 is linked to non-small cell lung carcinoma.